BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule inhibitors for cancers driven by RAS pathway signaling. Its pipeline targets KRAS and related nodes such as PI3K, aiming at both ON- and OFF-state RAS biology that underlies many solid tumors. The company was spun out of BridgeBio with dedicated external capital to advance precision oncology programs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -22.1 | — |
| Q2 2025 | 0 | — | -28.4 | — |
| Q3 2025 | 0 | — | -44.8 | — |
| Q4 2025 | 0 | — | -38.8 | — |
| Q1 2026 | 0 | — | -42.1 | — |
| Q2 2026 | 0 | — | -56.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AirJoule Technologies Corporation (AIRJ), AIAI Holdings Corporation (AIAI), Hongli Group Inc. (HLP), Amtech Systems, Inc. (ASYS), First Internet Bancorp (INBK), Better Home & Finance Holding Company (BETR)